AIM： To evaluate the efficacy of continuous regional arterial infusion therapy （CRAI） with gabexate mesilate and antibiotics for severe acute pancreatitis （SAP）. METHODS： We conducted a prospective study on pati...AIM： To evaluate the efficacy of continuous regional arterial infusion therapy （CRAI） with gabexate mesilate and antibiotics for severe acute pancreatitis （SAP）. METHODS： We conducted a prospective study on patients who developed SAP with or without CRAI. Out of 18 patients fulfilled clinical diagnostic criteria for SAP in Japan, 9 patients underwent CRAI, while 9 patients underwent conventional systemic protease inhibitor and antibiotics therapy （non-CRAI）. CRAI was initiated within 72 h of the onset of pancreatitis. Gabexate mesilate （2400 mg/d） was continuously administered for 3 to 5 d. The clinical outcome including serum inflammation-related parameters were examined. RESULTS- The duration of abdominal pain in the CRAI group was 1.9 =1：0.26 d, whereas that in the non-CRAI group was 4.3 ±0.50. The duration of SIRS in the CRAI group was 2.2 ± 0.22 d, whereas that in the non- CRAI group was 3.2 ± 0.28. Abdominal pain and SIRS disappeared significantly in a short period of time after the initiation of CRAI using gabexate mesilate. The average length of hospitalization significantly differed between the CRAI and non-CRAI groups, 53.3 ± 7.9 d and 87.4± 13.9 d, respectively. During the first two weeks, levels of serum CRP and the IL6/IL10 ratio in the CRAI group tended to have a rapid decrease compared to those in the non-CRAI group. CONCLUSION： The present results suggest that CRAI using gabexate mesilate was effective against SAP.展开更多
Gabexate mesilate（GM） is a trypsin inhibitor,and mainly used for treatment of various acute pancreatitis,including traumatic pancreatitis（TP）,edematous pancreatitis,and acute necrotizing pancreatitis. However,due ...Gabexate mesilate（GM） is a trypsin inhibitor,and mainly used for treatment of various acute pancreatitis,including traumatic pancreatitis（TP）,edematous pancreatitis,and acute necrotizing pancreatitis. However,due to the characteristics of pharmacokinetics,the clinical application of GM still needs frequently intravenous administration to keep the blood drug concentration,which is difficult to manage. Specially,when the blood supply of pancreas is directly damaged,intravenous administration is difficult to exert the optimum therapy effect. To address it,a novel thermosensitive in-situ gel of gabexate mesilate（GMTI） was developed,and the optimum formulation of GMTI containing 20.6%（w/w） P-407 and 5.79%（w/w） P188 with different concentrations of GM was used as a gelling solvent. The effective drug concentration on trypsin inhibition was examined after treatment with different concentrations of GMTI in vitro,and GM served as a positive control. The security of GMTI was evaluated by hematoxylin-eosin（HE） staining,and its curative effect on grade Ⅱ pancreas injury was also evaluated by testing amylase（AMS）,C-reactive protein（CRP） and trypsinogen activation peptide（TAP）,and pathological analysis of the pancreas. The trypsin activity was slightly inhibited at 1.0 and 5.0 mg/m L in GM group and GMTI group,respectively（P〈0.05 vs. P-407）,and completely inhibited at 10.0 and 20.0 mg/m L（P〈0.01 vs. P-407）. After local injection of 10 mg/m L GMTI to rat leg muscular tissue,muscle fiber texture was normal,and there were no obvious red blood cells and infiltration of inflammatory cells. Furthermore,the expression of AMS,CRP and TAP was significantly increased in TP group as compared with control group（P〈0.01）,and significantly decreased in GM group as compared with TP group（P〈0.01）,and also slightly inhibited after 1.0 and 5.0 mg/m L GMTI treatment as compared with TP group（P〈0.05）,and significantly inhibited after 10.0 and 20.0 mg/m L GMTI treatment as compared with TP group（P〈0.01）. HE staining results demonstrated that pancreas cells were uniformly distributed in control group,and they were loosely arranged,partially dissolved,with deeply stained nuclei in TP group. Expectedly,after gradient GMTI treatment,pancreas cells were gradually restored to tight distribution,with slightly stained nuclei. This preliminary study indicated that GMTI could effectively inhibit pancreatic enzymes,and alleviate the severity of trauma-induced pancreatitis,and had a potential drug developing and clinic application value.展开更多
A novel capacitive sensor for pazufloxacin mesilate (pazufloxacin) determination was developed by electropolymerizing p-aminobenzene sulfonic (p-ABSA) and molecularly imprinted polymers (MPs), which was synthesized th...A novel capacitive sensor for pazufloxacin mesilate (pazufloxacin) determination was developed by electropolymerizing p-aminobenzene sulfonic (p-ABSA) and molecularly imprinted polymers (MPs), which was synthesized through thermal radical copolymerization of metharylic acid (MAA) and ethylene glycol dimethacrylate (EGDMA) in the presence of pazufloxacin template molecules, on the gold electrode surface. Furthermore, 1-dedecanethiol was used to insulate the modified electrode. Alternating current (ac) impedance experiments were carried out with a Model IM6e to obtain the capacitance responses. Under the optimum conditions, the sensor showed linear capacitance response to pazufloxacin in the range of 5 ng·mL?1 to 5 μg·mL?1 with a relative standard deviation (RSD) 5.3% (n=7) and a detection limit of 1.8 ng·mL?1. The recoveries for different concentration levels of pazufloxacin samples varied from 94.0% to 102.0%. Electrochemical experiments indicated the capacitive sensor exhibited good sensitivity and selectivity and showed excellent parameters of regeneration and stability.展开更多
In the present study,we aimed to investigate the pharmacokinetics and dosage proportionality for a single,intravenous utilization of Pazufloxacin Mesilate Sodium Chloride,an injectable synthetic fluoroquinolone antiba...In the present study,we aimed to investigate the pharmacokinetics and dosage proportionality for a single,intravenous utilization of Pazufloxacin Mesilate Sodium Chloride,an injectable synthetic fluoroquinolone antibacterial agent,in healthy Chinese volunteers.In this open-labeled,three-dosage parallel study,subjects were randomized to receive a single dose of Pazufloxacin Mesilate at 150,300 or 600 mg(n=10,10 and 10,respectively)administered as a 30-min intravenous infusion.Blood and urine samples were serially collected from 0 to 24 h after drug administration.Moreover,the sample’s drug concentrations were analyzed via validated RP-HPLC method.Subjects receiving a single dose of Pazufloxacin Mesilate 150,300 or 600 mg were in accordance with the two compartment model.The Cmax for each dosage group was 2.37±0.89,4.27±0.74 and 10.74±4.06 mg·mL(–1),respectively;and the AUC0→∞was 3.24±1.2,5.89±1.51 and 13.32±2.35 mg·h·mL–1,respectively.In addition,Tmax for groups treated with 150,300 and 600 mg was 0.48±0.08,0.50±0.00 and 0.53±0.08 h,respectively.The correlation analysis for AUC0→∞,Cmax and dosage suggested that pazufolxacin mesilate displayed dose proportion at the dose ranging from 150 to 600 mg.The data suggested that all three different dosage regimens fit with the two compartment model.Meanwhile,it presented a linear correlation between AUC0→∞,Cmax and dosage over the range of 150–600 mg.展开更多
Idiopathic hypereosinophilic syndrome(HES) is a rare disorder characterized by peripheral eosinophilia exceeding 1500/mm3, a chronic course, absence of secondary causes, and signs and symptoms of eosinophil-mediated t...Idiopathic hypereosinophilic syndrome(HES) is a rare disorder characterized by peripheral eosinophilia exceeding 1500/mm3, a chronic course, absence of secondary causes, and signs and symptoms of eosinophil-mediated tissue injury. One of the best-characterized forms of HES is the one associated with FIP1L1-PDGFRA gene rearrangement, which was recently demonstrated as responsive to treatment with the small molecule kinase inhibitor drug, imatinib mesylate. Here, we describe the case of a 51-year-old male, whose symptoms satisfied the clinical criteria for HES with cutaneous and cardiac involvement and who also presented with vasculitic brain lesions and retroperitoneal bleeding. Molecular testing, including fluorescence in situ hybridization, of bone marrow and peripheral blood showed no evidence of PDGFR rearrangements. The patient was initially treated with high-dose steroid therapy and then with hydroxyurea, but proved unresponsive to both. Upon subsequent initiation of imatinib mesilate, the patient showed a dramatic improvement in eosinophil count and progressed rapidly through clinical recovery. Long-term follow-up confirmed the efficacy of treatment with low-dose imatinib and with no need of supplemental steroid treatment, notwithstanding the absence of PDGFR rearrangement.展开更多
基金Supported by Grant from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, No. 20590808The Research Committee of Intractable Diseases of the Pancreas, provided by the Ministry of Health, Labour, and Welfare Japan, No. 50253448
文摘AIM： To evaluate the efficacy of continuous regional arterial infusion therapy （CRAI） with gabexate mesilate and antibiotics for severe acute pancreatitis （SAP）. METHODS： We conducted a prospective study on patients who developed SAP with or without CRAI. Out of 18 patients fulfilled clinical diagnostic criteria for SAP in Japan, 9 patients underwent CRAI, while 9 patients underwent conventional systemic protease inhibitor and antibiotics therapy （non-CRAI）. CRAI was initiated within 72 h of the onset of pancreatitis. Gabexate mesilate （2400 mg/d） was continuously administered for 3 to 5 d. The clinical outcome including serum inflammation-related parameters were examined. RESULTS- The duration of abdominal pain in the CRAI group was 1.9 =1：0.26 d, whereas that in the non-CRAI group was 4.3 ±0.50. The duration of SIRS in the CRAI group was 2.2 ± 0.22 d, whereas that in the non- CRAI group was 3.2 ± 0.28. Abdominal pain and SIRS disappeared significantly in a short period of time after the initiation of CRAI using gabexate mesilate. The average length of hospitalization significantly differed between the CRAI and non-CRAI groups, 53.3 ± 7.9 d and 87.4± 13.9 d, respectively. During the first two weeks, levels of serum CRP and the IL6/IL10 ratio in the CRAI group tended to have a rapid decrease compared to those in the non-CRAI group. CONCLUSION： The present results suggest that CRAI using gabexate mesilate was effective against SAP.
基金supported by National Natural Science Foundation of China(No.81471682 and 81327003)
文摘Gabexate mesilate（GM） is a trypsin inhibitor,and mainly used for treatment of various acute pancreatitis,including traumatic pancreatitis（TP）,edematous pancreatitis,and acute necrotizing pancreatitis. However,due to the characteristics of pharmacokinetics,the clinical application of GM still needs frequently intravenous administration to keep the blood drug concentration,which is difficult to manage. Specially,when the blood supply of pancreas is directly damaged,intravenous administration is difficult to exert the optimum therapy effect. To address it,a novel thermosensitive in-situ gel of gabexate mesilate（GMTI） was developed,and the optimum formulation of GMTI containing 20.6%（w/w） P-407 and 5.79%（w/w） P188 with different concentrations of GM was used as a gelling solvent. The effective drug concentration on trypsin inhibition was examined after treatment with different concentrations of GMTI in vitro,and GM served as a positive control. The security of GMTI was evaluated by hematoxylin-eosin（HE） staining,and its curative effect on grade Ⅱ pancreas injury was also evaluated by testing amylase（AMS）,C-reactive protein（CRP） and trypsinogen activation peptide（TAP）,and pathological analysis of the pancreas. The trypsin activity was slightly inhibited at 1.0 and 5.0 mg/m L in GM group and GMTI group,respectively（P〈0.05 vs. P-407）,and completely inhibited at 10.0 and 20.0 mg/m L（P〈0.01 vs. P-407）. After local injection of 10 mg/m L GMTI to rat leg muscular tissue,muscle fiber texture was normal,and there were no obvious red blood cells and infiltration of inflammatory cells. Furthermore,the expression of AMS,CRP and TAP was significantly increased in TP group as compared with control group（P〈0.01）,and significantly decreased in GM group as compared with TP group（P〈0.01）,and also slightly inhibited after 1.0 and 5.0 mg/m L GMTI treatment as compared with TP group（P〈0.05）,and significantly inhibited after 10.0 and 20.0 mg/m L GMTI treatment as compared with TP group（P〈0.01）. HE staining results demonstrated that pancreas cells were uniformly distributed in control group,and they were loosely arranged,partially dissolved,with deeply stained nuclei in TP group. Expectedly,after gradient GMTI treatment,pancreas cells were gradually restored to tight distribution,with slightly stained nuclei. This preliminary study indicated that GMTI could effectively inhibit pancreatic enzymes,and alleviate the severity of trauma-induced pancreatitis,and had a potential drug developing and clinic application value.
基金Supported by the National Natural Science Foundation of China (Grant No. 20675064)the Natural Science Foundation of Chongqing City (Grant No. CSTC-2004BB4149 and 2005BB4100)High Technology Project Foundation of Southwest University (Grant No. XSGX02).
文摘A novel capacitive sensor for pazufloxacin mesilate (pazufloxacin) determination was developed by electropolymerizing p-aminobenzene sulfonic (p-ABSA) and molecularly imprinted polymers (MPs), which was synthesized through thermal radical copolymerization of metharylic acid (MAA) and ethylene glycol dimethacrylate (EGDMA) in the presence of pazufloxacin template molecules, on the gold electrode surface. Furthermore, 1-dedecanethiol was used to insulate the modified electrode. Alternating current (ac) impedance experiments were carried out with a Model IM6e to obtain the capacitance responses. Under the optimum conditions, the sensor showed linear capacitance response to pazufloxacin in the range of 5 ng·mL?1 to 5 μg·mL?1 with a relative standard deviation (RSD) 5.3% (n=7) and a detection limit of 1.8 ng·mL?1. The recoveries for different concentration levels of pazufloxacin samples varied from 94.0% to 102.0%. Electrochemical experiments indicated the capacitive sensor exhibited good sensitivity and selectivity and showed excellent parameters of regeneration and stability.
基金the support of Laboratory of National Institution of Drug Clinical Trial,Xiangya Hospital,Central South University
文摘In the present study,we aimed to investigate the pharmacokinetics and dosage proportionality for a single,intravenous utilization of Pazufloxacin Mesilate Sodium Chloride,an injectable synthetic fluoroquinolone antibacterial agent,in healthy Chinese volunteers.In this open-labeled,three-dosage parallel study,subjects were randomized to receive a single dose of Pazufloxacin Mesilate at 150,300 or 600 mg(n=10,10 and 10,respectively)administered as a 30-min intravenous infusion.Blood and urine samples were serially collected from 0 to 24 h after drug administration.Moreover,the sample’s drug concentrations were analyzed via validated RP-HPLC method.Subjects receiving a single dose of Pazufloxacin Mesilate 150,300 or 600 mg were in accordance with the two compartment model.The Cmax for each dosage group was 2.37±0.89,4.27±0.74 and 10.74±4.06 mg·mL(–1),respectively;and the AUC0→∞was 3.24±1.2,5.89±1.51 and 13.32±2.35 mg·h·mL–1,respectively.In addition,Tmax for groups treated with 150,300 and 600 mg was 0.48±0.08,0.50±0.00 and 0.53±0.08 h,respectively.The correlation analysis for AUC0→∞,Cmax and dosage suggested that pazufolxacin mesilate displayed dose proportion at the dose ranging from 150 to 600 mg.The data suggested that all three different dosage regimens fit with the two compartment model.Meanwhile,it presented a linear correlation between AUC0→∞,Cmax and dosage over the range of 150–600 mg.
文摘Idiopathic hypereosinophilic syndrome(HES) is a rare disorder characterized by peripheral eosinophilia exceeding 1500/mm3, a chronic course, absence of secondary causes, and signs and symptoms of eosinophil-mediated tissue injury. One of the best-characterized forms of HES is the one associated with FIP1L1-PDGFRA gene rearrangement, which was recently demonstrated as responsive to treatment with the small molecule kinase inhibitor drug, imatinib mesylate. Here, we describe the case of a 51-year-old male, whose symptoms satisfied the clinical criteria for HES with cutaneous and cardiac involvement and who also presented with vasculitic brain lesions and retroperitoneal bleeding. Molecular testing, including fluorescence in situ hybridization, of bone marrow and peripheral blood showed no evidence of PDGFR rearrangements. The patient was initially treated with high-dose steroid therapy and then with hydroxyurea, but proved unresponsive to both. Upon subsequent initiation of imatinib mesilate, the patient showed a dramatic improvement in eosinophil count and progressed rapidly through clinical recovery. Long-term follow-up confirmed the efficacy of treatment with low-dose imatinib and with no need of supplemental steroid treatment, notwithstanding the absence of PDGFR rearrangement.
